Pancreatic Cancer Research

ResearcherNational Institutes of HealthActive in the last 2 years

Katerina Hadrava Vanova

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8868-6013; OpenAlex author ID A5082229158. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 3

  1. Opsonization and timing as key determinants of MBTA immunotherapy efficacy in pancreatic adenocarcinoma and recurrence treatment. Co-author DOI 10.1080/15384047.2026.2683273↗
  2. Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells. Co-author DOI 10.1186/s12885-016-2343-9↗
  3. Antiproliferative effects of carbon monoxide on pancreatic cancer. Co-author DOI 10.1016/j.dld.2013.12.007↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jan Ženka · 1 shared paper, 2026 · strength 0.28
  2. David Větvička · 1 shared paper, 2026 · strength 0.28
  3. Andrea Frejlachova · 1 shared paper, 2026 · strength 0.28
  4. Ondřej Uher · 1 shared paper, 2026 · strength 0.28
  5. Tomáš Ruml · 2 shared papers, 2014–2016 · strength 0.10
  6. Helena Gbelcová · 2 shared papers, 2014–2016 · strength 0.10
  7. Libor Vı́tek · 2 shared papers, 2014–2016 · strength 0.10
  8. R Gürlich · 1 shared paper, 2016 · strength 0.06
  9. Jiřı́ Neužil · 1 shared paper, 2016 · strength 0.06
  10. Štěpána Boukalová · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.